Brown Brothers Harriman & Co’s Sarepta Therapeutics SRPT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.5K	Hold	4,370	–	–	﹤0.01%	1034
2026 Q1	$95.1K	Sell	4,370 -3	-0.1%	-$58	﹤0.01%	945
2025 Q4	$94.1K	Sell	4,373 -1,281	-23%	-$27K	﹤0.01%	916
2025 Q3	$109K	Buy	5,654 +1,284	+29%	+$22.9K	﹤0.01%	840
2025 Q2	$74.7K	Hold	4,370	–	–	﹤0.01%	857
2025 Q1	$279K	Sell	4,370 -24	-0.5%	-$2.53K	﹤0.01%	497
2024 Q4	$534K	Hold	4,394	–	–	﹤0.01%	396
2024 Q3	$549K	Buy	4,394 +24	+0.5%	+$3.32K	﹤0.01%	387
2024 Q2	$690K	Hold	4,370	–	–	0.01%	336
2024 Q1	$566K	Hold	4,370	–	–	﹤0.01%	343
2023 Q4	$421K	Sell	4,370 -93	-2%	-$8.92K	﹤0.01%	371
2023 Q3	$541K	Buy	4,463 +93	+2%	+$10.5K	﹤0.01%	333
2023 Q2	$500K	Sell	4,370 -6,000	-58%	-$774K	﹤0.01%	328
2023 Q1	$1.43M	Hold	10,370	–	–	0.01%	211
2022 Q4	$1.34M	Hold	10,370	–	–	0.01%	192
2022 Q3	$1.15M	Hold	10,370	–	–	0.01%	202
2022 Q2	$777K	Hold	10,370	–	–	0.01%	251
2022 Q1	$810K	Hold	10,370	–	–	0.01%	275
2021 Q4	$934K	Hold	10,370	–	–	0.01%	252
2021 Q3	$959K	Hold	10,370	–	–	0.01%	232
2021 Q2	$806K	Hold	10,370	–	–	﹤0.01%	261
2021 Q1	$773K	Hold	10,370	–	–	﹤0.01%	253
2020 Q4	$1.77M	Hold	10,370	–	–	0.01%	172
2020 Q3	$1.46M	Hold	10,370	–	–	0.01%	175
2020 Q2	$1.66M	Sell	10,370 -3,000	-22%	-$408K	0.01%	162
2020 Q1	$1.31M	Hold	13,370	–	–	0.01%	172
2019 Q4	$1.73M	Sell	13,370 -3	-0%	-$303	0.01%	180
2019 Q3	$1.01M	Sell	13,373 -5	-0%	-$590	0.01%	224
2019 Q2	$2.03M	Buy	13,378 +8	+0.1%	+$972	0.01%	156
2019 Q1	$1.59M	Hold	13,370	–	–	0.01%	171
2018 Q4	$1.46M	Hold	13,370	–	–	0.01%	167
2018 Q3	$2.16M	Sell	13,370 -12,000	-47%	-$1.64M	0.01%	143
2018 Q2	$3.35M	Hold	25,370	–	–	0.02%	119
2018 Q1	$1.88M	Sell	25,370 -3,000	-11%	-$200K	0.01%	140
2017 Q4	$1.58M	Sell	28,370 -3,000	-10%	-$159K	0.01%	157
2017 Q3	$1.42M	Hold	31,370	–	–	0.01%	154
2017 Q2	$1.06M	Hold	31,370	–	–	0.01%	165
2017 Q1	$929K	Hold	31,370	–	–	0.01%	177
2016 Q4	$860K	Hold	31,370	–	–	﹤0.01%	175
2016 Q3	$1.93M	Sell	31,370 -630	-2%	-$19K	0.01%	140
2016 Q2	$610K	Hold	32,000	–	–	﹤0.01%	209
2016 Q1	$625K	Hold	32,000	–	–	﹤0.01%	205
2015 Q4	$1.24M	Hold	32,000	–	–	0.01%	176
2015 Q3	$1.03M	Hold	32,000	–	–	0.01%	187
2015 Q2	$974K	Hold	32,000	–	–	﹤0.01%	202
2015 Q1	$425K	Hold	32,000	–	–	﹤0.01%	275
2014 Q4	$463K	Hold	32,000	–	–	﹤0.01%	264
2014 Q3	$675K	Hold	32,000	–	–	﹤0.01%	230
2014 Q2	$953K	Buy	32,000 +1,000	+3%	+$31.6K	﹤0.01%	210
2014 Q1	$745K	Sell	31,000 -31,000	-50%	-$790K	﹤0.01%	206
2013 Q4	$1.26M	Buy	62,000 +31,000	+100%	+$921K	﹤0.01%	221
2013 Q3	$1.46M	Buy	31,000 +30,000	+3,000%	+$1.16M	0.01%	160
2013 Q2	$38K	Buy	+1,000	New	+$35.8K	﹤0.01%	567

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Brown Brothers Harriman & Co's SRPT Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 4,370 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Brown Brothers Harriman & Co first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.35M in Q2 2018. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Brown Brothers Harriman & Co held 4,370 shares of Sarepta Therapeutics worth $78.5K as of Q2 2026.
Brown Brothers Harriman & Co left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1034 holding.
Brown Brothers Harriman & Co first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
Brown Brothers Harriman & Co's Sarepta Therapeutics position peaked at $3.35M in Q2 2018.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.